Stratasys and Ricoh co-sponsor clinical study
comparing the efficacy of 3D printed models to traditional CT or
MRI scanning for bone tumor excision planning
EXTON,
Pa. and EDEN PRAIRIE, Minn.
and REHOVOT, Israel,
June 26,
2024 /PRNewswire/ -- Ricoh USA, Inc. and Stratasys Ltd. (NASDAQ:
SSYS) today announced the enrollment of the first patient in a
groundbreaking clinical study aimed to evaluate the use of 3D
printed models for orthopedic oncology. The study will assess the
efficacy of patient-specific 3D printed anatomical models for
preoperative planning and tumor excision in comparison to the
current standard of care, which relies solely on CT or MRI
imaging.
The joint research aims to demonstrate potential improvements in
surgical outcomes, including reduced blood loss, shorter operating
time including time under anesthesia, and decreased risk of
procedural complications. To do this, clinical outcomes will be
compared between an experimental group in which tumors are excised
using 3D printed models alongside imaging for planning, and an
active comparator group in which tumor excision will be prepped
solely with imaging.
Benefits for medical staff and patients
The benefits of 3D printed models in preoperative planning are
severalfold and positively impact both medical practitioners and
patients alike. Doctors and surgeons benefit from improved and more
informed presurgical planning and practicing prior to operations,
making complex procedures more efficient, economical and faster.
Unlike the limitations of computer images, this enables doctors to
represent vital aspects of patient anatomy with life-size physical
replicas, granting them the means to simulate procedures and aid in
their precision of excision, ultimately reducing the chances of a
positive margin. In turn, the availability of accurate 3D printed
models to better communicate planned procedures, together with a
greatly improved surgical process, helps to improve patient outcome
and recovery.
The prospective, multi-center randomized controlled study is
expected to run for 12 months and involve up to 150 subjects across
three sites. The two sites which have agreed at this time to
participate are The Ohio State University Wexner Medical
Center and Corewell Health™, based in Michigan.
"Our never-ending mission is to improve patient outcomes, and
that starts with preoperative planning," said Kyle K. VanKoevering, MD Associate Professor,
Otolaryngology - Head and Neck Surgery, Ohio State Wexner Medical
Center. "We look forward to participating in this study to examine
how 3D printed models may help the medical staff better prepare for
surgery as well as improve patient education."
"Being one of the sites to participate in this study puts us on
the forefront of demonstrating new technologies that can advance
patient care and improve health outcomes," said Aws Hammad, M.D., clinical faculty of
orthopaedic surgery at Corewell Health William Beaumont University
Hospital. "Addressing the challenges that come along with bone
sarcomas and utilizing the power of patient-specific 3D modeling is
a significant step in not only patient education but as an aid to
surgeons for more precise surgical procedures."
According to Erez Ben Zvi, VP
Medical at Stratasys, "The collaboration brings together
unparalleled experience and innovation in medical imaging and 3D
printing and, if successful, may establish anatomical models as a
new standard for patient treatment in tumor removal from
bones."
Gary Turner, Managing Director,
Additive Manufacturing, Ricoh USA,
Inc., comments, "We are thrilled to co-sponsor this important
clinical trial alongside our longstanding partners at Stratasys to
further demonstrate the potential impact of 3D patient-specific
modeling as well as accelerate adoption of this technology to
better serve a broader population."
About Stratasys
Stratasys is leading the global shift
to additive manufacturing with innovative 3D printing solutions for
industries such as aerospace, automotive, consumer products and
healthcare. Through smart and connected 3D printers, polymer
materials, a software ecosystem, and parts on demand, Stratasys
solutions deliver competitive advantages at every stage in the
product value chain. The world's leading organizations turn to
Stratasys to transform product design, bring agility to
manufacturing and supply chains, and improve patient care.
To learn more about Stratasys, visit www.stratasys.com, the
Stratasys blog, X/Twitter, LinkedIn, or Facebook. Stratasys
reserves the right to utilize any of the foregoing social media
platforms, including Stratasys' websites, to share material,
non-public information pursuant to the SEC's Regulation FD. To the
extent necessary and mandated by applicable law, Stratasys will
also include such information in its public disclosure filings.
| About Ricoh |
Ricoh is a leading provider of integrated digital services and
print and imaging solutions designed to support digital
transformation of workplaces, workspaces and optimize business
performance.
Headquartered in Tokyo, Ricoh's
global operation reaches customers in approximately 200 countries
and regions, supported by cultivated knowledge, technologies, and
organizational capabilities nurtured over its 85-year history. In
the financial year ended March 2024,
Ricoh Group had worldwide sales of 2,348
billion yen (approx. 15.5 billion
USD).
It is Ricoh's mission and vision to empower individuals to find
Fulfillment through Work by understanding and transforming how
people work so we can unleash their potential and creativity to
realize a sustainable future.
For further information, please visit www.ricoh.com
© 2024 Ricoh USA, Inc. All rights reserved. All referenced
product names are the trademarks of their respective companies.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/first-patient-enrolled-in-landmark-clinical-study-to-assess-3d-printed-models-for-orthopedic-tumor-removal-302182531.html
SOURCE Ricoh USA, Inc.